A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

A Montgomery County, Pennsylvania patient will be one of the country's first patients to receive a newly FDA-approved ...

With a reduction in borrowing costs and consequent availability of cheaper capital, drugmakers can ramp up their R&D spending ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 600.18% and ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

The event, reportedly attended by over 10,500 people, highlighted the talents of the musicians while emphasizing the importance of inclusion. Information ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.